Core Viewpoint - The company reported a significant divergence in its 2025 annual performance, with a decline in net profit attributable to shareholders but a substantial increase in net profit after excluding non-recurring gains, indicating an improvement in the core business profitability [1]. Group 1: Financial Performance - The company's net profit attributable to shareholders is expected to decline significantly due to the absence of one-time gains from asset disposals, which inflated the previous year's profit base [1]. - The adjusted net profit, excluding non-recurring items, is projected to reach between 5.7 million and 8.5 million, representing a year-on-year increase of 46.51% to 118.49% [1]. - The company achieved a gross profit margin of 18.04% by the end of September 2025, an increase of 4.03 percentage points year-on-year [3]. Group 2: Business Operations - The subsidiary, Chongqing Nansong Pharmaceutical Technology Co., Ltd., has become a key profit driver, with a net profit of 12.11 million in the first three quarters of 2025, reflecting a year-on-year growth of 213.28% [2]. - Cost reduction and efficiency enhancement measures have led to a significant decrease in management expenses by 29.91% and financial expenses by 80.07% due to the repayment of loans from controlling shareholders [2]. - The net cash flow from operating activities reached 42.72 million, a substantial increase of 559.64% year-on-year, indicating enhanced cash generation capability from core operations [3]. Group 3: Debt and Cash Flow Management - The company's debt-to-asset ratio improved to 36.88%, a decrease of 18.48 percentage points year-on-year, alleviating debt repayment pressure [3]. - The third quarter of 2025 showed a notable recovery, with quarterly revenue of 48.62 million, a year-on-year increase of 26.76%, marking the end of a previous decline [3].